Mark Christopher Bradley Sells 2,572 Shares of Alumis (NASDAQ:ALMS) Stock

Alumis Inc. (NASDAQ:ALMS) insider Mark Christopher Bradley sold 2,572 shares of Alumis stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $26.37, for a total value of $67,823.64. Following the completion of the sale, the insider owned 48,533 shares in the company, valued at approximately $1,279,815.21. This trade represents a 5.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Alumis Stock Performance

NASDAQ:ALMS opened at $27.80 on Friday. The stock has a fifty day moving average price of $25.50 and a two-hundred day moving average price of $25.25. The stock has a market capitalization of $3.54 billion, a price-to-earnings ratio of -14.04 and a beta of -0.69. Alumis Inc. has a 1 year low of $3.76 and a 1 year high of $31.35.

Alumis (NASDAQ:ALMS) last issued its earnings results on Thursday, May 14th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.01). Alumis had a negative return on equity of 88.79% and a negative net margin of 2,825.70%.The company had revenue of $1.74 million for the quarter, compared to analysts’ expectations of $2.10 million. On average, analysts predict that Alumis Inc. will post -2.87 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALMS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Alumis by 64.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,535 shares of the company’s stock worth $77,000 after purchasing an additional 4,926 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of Alumis by 24.0% in the first quarter. Goldman Sachs Group Inc. now owns 61,645 shares of the company’s stock valued at $378,000 after buying an additional 11,949 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Alumis during the first quarter valued at approximately $111,000. Rhumbline Advisers lifted its stake in shares of Alumis by 21.7% during the first quarter. Rhumbline Advisers now owns 16,543 shares of the company’s stock valued at $102,000 after buying an additional 2,949 shares during the period. Finally, Geode Capital Management LLC boosted its position in Alumis by 163.2% during the second quarter. Geode Capital Management LLC now owns 1,167,832 shares of the company’s stock worth $3,504,000 after acquiring an additional 724,133 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Citigroup reaffirmed a “buy” rating on shares of Alumis in a report on Tuesday, May 19th. Wall Street Zen cut Alumis from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Chardan Capital raised their price objective on Alumis from $38.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, May 19th. Wells Fargo & Company boosted their target price on Alumis from $49.00 to $51.00 and gave the stock an “overweight” rating in a research report on Friday, May 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Alumis in a report on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $40.30.

Key Headlines Impacting Alumis

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Institutional ownership has generally increased, including a significant expansion of Geode Capital Management’s position and additional buying by Goldman Sachs, Rhumbline Advisers and other investors. Such activity may provide some support for Alumis shares, although the reported purchases occurred in prior quarters.
• Neutral Sentiment: HC Wainwright reaffirmed a “Neutral” rating on ALMS and maintained a $25 price target, suggesting the firm does not currently see a catalyst strong enough to support a more bullish outlook. HC Wainwright Reaffirms Neutral Rating for Alumis
• Negative Sentiment: Six insiders collectively sold 14,953 shares of Alumis at an average price of $26.37, generating approximately $394,311. Sellers included CFO John R. Schroer, whose position fell 11.72%, along with Mark Christopher Bradley, Jorn Drappa, David M. Goldstein, Roy C. Hardiman and Sanam Pangali. The transactions reduced individual holdings by roughly 1.28% to 12.28% and could weigh on investor sentiment because of the concentration of sales. However, insider sales can also reflect personal financial planning rather than a change in the company’s outlook. Alumis Insider Sale Filings
• Negative Sentiment: Alumis remains a clinical-stage biotechnology company with substantial losses. Its latest quarterly results missed both earnings and revenue expectations, while analysts forecast a full-year loss of approximately $2.87 per share. This limits fundamental support until the company reports meaningful clinical or development progress.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.